Physician Notification Letter for Aortic Stenosis

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Aortic StenosisPhysician Notification Letter - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is looking at whether electronic provider notification of severe aortic stenosis impacts its management, on the utilization of aortic valve replacement, and on ethnic and racial disparities in AVR utilization.

Eligible Conditions
  • Aortic Stenosis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: 1 year

1 year
Establish impact of electronic physician notification letter on the likelihood of AVR utilization for patients with a clinical indication for severe AS
Impact on mortality rate
Impact on proportion of patients referred to Cardiology/Heart Valve Team
Impact on rate of heart failure hospitalization
Impact on rate of trans-thoracic echocardiogram utilization and frequency of surveillance

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Control Group
1 of 2
Notification Letter Arm
1 of 2

Active Control

Experimental Treatment

940 Total Participants · 2 Treatment Groups

Primary Treatment: Physician Notification Letter · No Placebo Group · N/A

Notification Letter Arm
Behavioral
Experimental Group · 1 Intervention: Physician Notification Letter · Intervention Types: Behavioral
Control GroupNoIntervention Group · 1 Intervention: Control Group · Intervention Types:

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,699 Previous Clinical Trials
30,842,192 Total Patients Enrolled
Edwards LifesciencesIndustry Sponsor
164 Previous Clinical Trials
58,060 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: